Anti-CD3 Bispecific Antibody Affinity Tuning for Lower Cytokine Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific antibodies for cancer treatment face challenges in achieving an optimal balance between potency and toxicity, particularly due to high-affinity CD3 binding leading to cytokine release syndrome and impaired tumor antigen-dependent tissue distribution.
Innovation Solution
Development of optimized anti-CD3 antibodies with reduced binding to CD3 on T cells and a novel bispecific format that allows bivalent binding to tumor antigens and functional monovalent binding to CD3, minimizing toxicity while maintaining efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity CD3 binding is used to enhance cytolytic synapse formation and tumor cell clearance, then potency is improved, but cytokine release syndrome and toxicity increase
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the affinity of the anti-CD3 arm through amino acid substitutions in the CDR regions. Multiple variants (e.g., 1a, 3b, 2b1) with progressively reduced affinity were generated and characterized. The optimal variant (1a3b2b1) achieved a balance where affinity was sufficient for tumor cell killing but reduced enough to minimize cytokine release syndrome, directly resolving the contradiction between potency and toxicity.
2Reliability
If high CD3 binding affinity is used to enhance T cell activation, then tumor cell killing is improved, but tissue distribution is impaired and accumulation in T cell compartment increases
Solution Approach 1:
The patent uses parameter changes to optimize the kinetic parameters of CD3 binding. By reducing the affinity through specific amino acid substitutions, the patent achieved better tissue distribution characteristics. The optimized variant demonstrated improved ability to reach tumor sites while reducing unwanted accumulation in T cell-rich compartments, thus resolving the tissue distribution issue.
3Productivity
If polyclonal T cell activation is driven by T-cell engager bispecific antibodies, then tumor cell clearance is enhanced, but fatal cytokine release syndrome occurs
Solution Approach 1:
The patent applies local quality by creating spatially selective T cell activation. The bispecific antibody is designed to preferentially activate T cells at the tumor site through bivalent tumor antigen binding combined with monovalent CD3 binding. This localized activation mechanism enhances tumor cell clearance while minimizing systemic cytokine release, as the immune activation is confined to the tumor microenvironment rather than occurring systemically.
Solution Approach 2:
The patent segments the binding functions by creating asymmetric valency: bivalent binding to tumor antigens (CEA) and monovalent binding to CD3. This segmentation allows the antibody to strongly anchor at tumor cells through two tumor antigen interactions while presenting only one CD3 binding site, thereby reducing excessive T cell activation and cytokine release while maintaining effective tumor cell killing.
Data Source
AI summary
The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present invention also provides bispecific antigen binding molecules for activating T cells. In addition, the invention further provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising the above said bispecific antigen binding molecules.